AMSBIO
AMSBIO is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries.
Latest AMSBIO Content
Product News
Aptamers for Cancer Diagnosis and Therapy
AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer.
Product News
Clinical-Grade Recombinant Proteins for Cell Therapy
AMSBIO announces the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
Product News
Isolation of High Purity Exosomes
AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
Product News
Crucial Tools for COVID-19 Omicron Research
AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.
Product News
One-Step ELISA Experiments
AMSBIO announces the launch of the QuicKey Pro™ range of ELISA kits – new easy-to-use assays that require just one step of washing, and one step of sample addition, resulting in a whole experiment taking only 90 minutes.
Product News
US Research Reveals the Role of Heparan Sulfate in Obesity
AMSBIO reports how researchers at the Washington University School of Medicine (St. Louis, USA) have used their 10E4 Heparan Sulfate (HS) antibody in pioneering obesity research to quantify the role of HS in the process of intercellular mitochondria transfer to macrophages.
Product News
Expanded Range of Nucleic Acid Extraction Kits for Pathogens Detection
AMSBIO announce the addition of several new products to its growing range of magnetic bead-based nucleic acid extraction kits for pathogens detection.
Product News
AMSBIO Expands EU Operations
Life science specialists, AMSBIO, have made a new strategic investment to enhance the level of support to its sizeable and growing base of customers across the European Union.
Product News
Latest Tools for COVID-19 Omicron Variant Research
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.
Advertisement
